Breaking News

ACM Global Relocates to Expanded Facilities

November 27, 2012

York facility offers 14,500 sq. ft. of lab and office space

ACM Global Central Lab has relocated its facilities to York, England. The larger facility offers 14,500 sq. ft. of lab and office space and accommodates ACM’s expanding lab operations, and growing staff of data analysts, project managers and quality assurance specialists.
 
“Our new facility enables us to continue our growth in the European market and to expand the menu of clinical trials testing services we offer our clients,” said Jerry Boxall, managing director, Europe at ACM Global Central Laboratory. “We are excited with the prospects offered by our new facility, which has been purpose-built to optimize our laboratory processes. The additional space enhances our ability to continue to meet the needs of our clients with high-quality laboratory services, while positioning us to take advantage of new opportunities in the market.”
 
“Expansion of our European laboratory hub represents a significant investment by our company, driven by our growth over the last several years,” said Angela J. Panzarella, president of ACM Medical Laboratory, Inc., the parent company of ACM Global Central Lab. “We have enjoyed robust growth in our European and global business, and the new facility represents our commitment to the region and to continuous improvement of the services we offer our clients.”
  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials